Paul Hudson, the former CEO of Sanofi, abruptly left in February, had a strong focus on innovation. Upon taking over the reins of the French pharmaceutical giant in 2019, the British executive embarked on a vast transformation to refocus the company’s portfolio towards innovative drugs, with the ambition of becoming a champion in immunology. However, this strategy failed to convince the markets, ultimately leading to his departure. While awaiting the arrival of his successor, Belén Garijo, currently the CEO of the German laboratory Merck KGaA, on April 26, Sanofi continues its momentum.
The French group, which reported a revenue of €43.62 billion in 2025 (+9.9% year-on-year), announced on Tuesday, March 31, a partnership with the startup campus giant, Station F, to position itself at the forefront of capturing innovation at its source.
“This partnership will fully integrate cutting-edge technologies such as artificial intelligence, digital modeling, and data analytics at the heart of our R&D activities,” explained Challenges Houman Ashrafian, Sanofi’s Executive Vice President in charge of Research and Development.
Starting from mid-May, a first selection of startups will collaborate with Sanofi’s digital and scientific teams on targeted projects for six months. These startups will be able to test their technologies under real conditions, leveraging Sanofi’s scientific expertise and proprietary data.
These projects, aimed at validating and accelerating the deployment of the most promising technological solutions, will align with the group’s strategic priorities, particularly in immunology and treatment discovery. Biological data analysis on a large scale, modeling immune system mechanisms, and developing predictive tools for disease research are some of the key focus areas.
Context: The article describes Sanofi’s partnership with Station F to enhance innovation in its R&D activities.
Fact Check: The former CEO of Sanofi, Paul Hudson, aimed to transform the company into a leader in immunology, but his strategy did not resonate well with the markets, leading to his departure.
